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Purpose: Lamivudine is known to be very effective in
suppressing hepatitis B virus replication and virus induced
necroinflammation. The aim of this study was to evaluate
lamivudine therapy efficacy, predictive factors, breakthrough,
prevalence of YMDD mutation, and relapse rate in Korean
children with chronic hepatitis B. Materials and Methods:
Between August 1999 and February 2005, 60 children on
lamivudine therapy for chronic hepatitis B were enrolled.
Treatment response was defined as alanine aminotransferase
(ALT) normalization, and HBeAg and HBV-DNA disap-
pearance. Results: Seroconversion rates of HBeAg and HBV-
DNA were 42% and 53%, respectively, and ALT normalization
rate was 88%. Seroconversion rates of HBeAg (60.0%) and
anti-HBe (60.0%) were higher in patients younger than 6
years. Seroconversion rate of HBV-DNA (68.4%) and
normalization rate of serum ALT (94.7%) were highest in
patients between 6 and 12 years. Seroconversion rates of all
HBV markers were lowest in patients older than 12 years.
Predicted 3 year cumulative seroconversion rates, were 70%,
68% for HBeAg, HBV-DNA, respectively. These were
calculated by Kaplan-Meier method. Cox proportional hazard
regression model showed that pre-treatment ALT was a
positive predictive factor for seroconversion of HBeAg and
HBV-DNA. Breakthrough phenomenon was noted in 6 patients,
and 3 had a YMDD mutation. Conclusion: Lamivudine
therapy had a significant effect on HBeAg seroconversion and
HBV-DNA disappearance, and ALT normalization for Korean
children with chronic hepatitis B.
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INTRODUCTION
Worldwide, 2 billion people have been infected
with hepatitis B virus (HBV) and more than 350
million are chronic carriers. Approximately 25% to
40% of carriers will develop cirrhosis or
hepatocellular carcinoma (HCC).
1 In Korea, Choi
et al.
2 reported a 12.3% carrier rate in 1983. With
introduction of HBV vaccination, the carrier rate
decreased to 0.4 - 0.7%.
3,4 Treatment with early
anti-viral therapy aims to reduce complications,
including liver cirrhosis and hepatocellular
carcinoma.
Previous anti-viral and immunosuppressive
treatments for HBV were ineffective and dis-
continued. Current anti-viral treatment includes
interferon-alpha (IFN) and lamivudine. Lamivudine
is the derivative of pyrimidine, and although
originally developed as an anti-viral for human
immunodeficiency virus (HIV), was found to
selectively repress HBV-DNA polymerase.
5 A
disadvantage of lamivudine is that HBV-DNA
mutation can develop, and emergence of the wild
type virus can occur after drug cessation.
6-8 The
present study aims to assess the efficacy of
lamivudine therapy, breakthrough, prevalence of
YMDD mutation, and the relapse rate in children
with chronic hepatitis B.
MATERIALS AND METHODS
Patients
Sixty patients diagnosed with chronic hepatitis
B at Severance Children Hospital, Yonsei University
College of Medicine, were enrolled in this cohort
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study between August 1999 and February 2005.
Inclusion criteria for lamivudine therapy included
increased serum aminotransferase activity (at least
two times the upper normal limit) and a minimum
6 month presence of HBsAg, HBeAg, and HBV-
DNA markers. Liver biopsies were not performed.
All patients were treated with lamivudine (Glaxo
Wellcome Research and Development Ltd.,
Greenford, England). Serum total bilirubin (T.bil),
alkaline phosphatase (ALP), cholesterol, albumin,
AST, ALT, HBeAg, anti-HBe, and HBV-DNA were
measured every 3 to 6 months. Enzyme immu-
noassay (Abbott Laboratories, North Chicago, IL)
was used to examine HBeAg and anti-HBe. Solution
hybridization technique (Hybrid Capture; Digene
Diagnostics, Beltsville, MD, USA) was used to
detect HBV-DNA, and values greater than 0.5
pg/dL (> 141,500 copies/mL using RT-PCR) were
considered positive. Positive response to lamivudine
therapy was defined as seroconversion of HBeAg
and anti-HBe, undetectable serum HBV-DNA, and
normalization of serum aminotransferase. Patients
were divided into 3 groups based on virologic and
serologic response to therapy, which were
responders (normalized HBeAg, anti-HBe, HBV-
DNA, and serum aminotransferase), partial
responders (normalized serum aminotransferase
but only HBeAg or HBV-DNA seroconversion),
and non-responders (no change in HBeAg, anti-
HBe, and HBV-DNA). In patients with break-
through (ALT increased more than two times the
upper normal limit and HBV-DNA greater than
141,500 copies/mL using PCR), YMDD mutation
was evaluated by using nested polymerase chain
reaction and restriction-fragment- length polymor-
phism assay.
9 Many reports in Korea said that
genotype C HBV prevails predominantly among
chronic carriers of the virus in Korea (80 - 100%),
irrespective of their age, clinical stages of liver
disease and geographic origin.
10-13 So HBV
genotyping was skipped because of previous
reports.
Statistical analysis
Patients who visited hospital had each deferent
initiation time of lamivudine. Because of out
national insurance, we could not define the
duration of therapy. SPSS (version 12.0) was used
for statistical analysis. To evaluate long-term
treatment results, Kaplan-Meier method was used
to predict the cumulative seroconversion rate. Cox
proportional hazard regression model was used to
evaluate correlations between HBV marker
seroconversion and age, gender, serum ALT, and
HBV-DNA. Frequency and cross-tabulation an-
alysis were also used. Results were considered
significant at the p < 0.05 level.
RESULTS
Clinical characteristics of patients
Sixty patients were diagnosed with chronic
hepatitis B between August 1999 and February
Table 1. Clinical Characteristics of Patients with Chronic Hepatitis B
Responders Partial responders Non-responders Total
No. of patients 24 (40%) 8 (13.3%) 28 (47.7%) 60 (100%)
Gender (M : F) 16 : 8 7 : 1 16 : 12 39 : 21
Age (yrs) 13.1 ± 6.9 12.9 ± 5.2 13.9 ± 7.2 13.4 ± 6.8
F/U (months) 22.5 ± 13.4 15.8 ± 6.7 27.1 ± 38.6 23.8 ± 28.0
Duration of Tx. (months) 15.3 ± 5.0 15.6 ± 6.6 17.5 ± 9.0 16.4 ± 7.3
ALT (IU/L) 310.8 ± 301.8 299.3 ± 308.9 121.8 ± 114.5 221.1 ± 248.2
AST (IU/L) 162.0 ± 125.4 108.8 ± 63.8 81.2 ± 81.1 117.2 ± 105.2
HBV-DNA (pg/dL) 1064.9 ± 1194.1 1553.5 ± 1210.2 1973.2 ± 1833.5 1553.9 ± 1564.8
ALT, alanine aminotransferase; AST, aspartate aminotransferase.Lamivudine Therapy for Children with Chronic Hepatitis B
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2005. The mean duration of therapy was 16.4 ± 7.3
months, and the mean follow-up duration was
23.8 ± 28.0 months. Twenty-four (40%) patients
were considered responders, 8 (13.3%) partial
responders, and 28 (47.7%) non-responders. The
pre-treatment ALT and AST values of the res-
ponder group were significantly higher compared
to other groups (p = 0.013, p = 0.020, respectively).
There was no significant difference of serum
HBV-DNA among the 3 groups (p = 0.08) (Table
1). Family history of chronic hepatitis B was noted
in 81.7% of children.
Therapeutic efficacy of lamivudine
Following lamivudine therapy, seroconversion
of HBV-DNA, HBeAg, and anti-HBe were noted
in 32 (53%), 25 (42%), and 25 (42%) patients,
respectively. Seroconversion of both HBeAg and
HBV-DNA, HBV-DNA only, and HBeAg only
occurred in 24 (40%), 8 (13%), and 1 (1.7%) patient,
respectively. Serum ALT normalized in 53 (88%)
patients (Table 2). The mean time to seroconversion
for HBV-DNA, HBeAg, and anti-HBe was 7.2 ±
6.4, 11.2 ± 8.1, and 11.4 ± 7.9 months, respectively.
Normalization of serum ALT took 5.3 ± 5.2 months
(Table 3). Seroconversion rates of HBeAg (60.0%)
and anti-HBe (60.0%) were higher in patients
younger than 6 years. Seroconversion rate of HBV-
DNA (68.4%) and normalization rate of serum
ALT (94.7%) were highest in patients between 6
and 12 years. Seroconversion rates of all HBV
markers were lowest in patients older than 12
years (Table 4). Seroconversion rates of HBeAg
(63.6%), anti-HBe (63.6%), and HBV-DNA (72.7%)
were higher in patients with pre-treatment ALT
values > 300 IU/dL (Table 5). Seroconversion rates
of HBeAg (56.5%), anti-HBe (60.9%) and HBV-
DNA (65.2%) were higher in patients with pre-
treatment HBV-DNA < 500 pg/dL (Table 6).
The predicted cumulative seroconversion rate
for 3 years after initiation of lamivudine therapy
was calculated using Kaplan-Meier method.
Predicted cumulative seroconversion rates of
HBeAg, anti-HBe, and HBV-DNA were 70%, 65%,
and 68%, respectively (Fig. 1, 2, and 3). All
cumulative seroconversion rates were sustained
until 5 years after initiation of therapy.
The effects of pre-treatment age, gender, and
serum ALT and HBV-DNA on seroconversion
rates were assessed with Cox proportional hazard
regression model. Age, gender, and pre-treatment
Table 2. Prevalence of Virologic and Serologic Response
No. of patients
HBeAg (-) 25 (42%)
anti-HBe (+) 25 (42%)
HBV-DNA (-) 32 (53%)
HBeAg (-) & HBV-DNA (-) 24 (40%)
HBeAg (+) & HBV-DNA (-) 8 (13%)
HBeAg (-) & HBV-DNA (+) 1 (0.02%)
Normalization of ALT 53 (88%)
Total 60 (100%)
Table 3. Dutation of Response
Duration of response
(months; mean ± SD)
Negative conversion of HBeAg 11.2 ± 8.1
Positive conversion of anti-HBe 11.4 ± 7.9
Negative conversion of HBV-
DNA
7.2 ± 6.4
Normalization of ALT 5.3 ± 5.2
Table 4. Virologic Response and Age
HBeAg (-) anti-HBe (+) HBV-DNA (-)
< 6 (n = 10) 6 (60.0%) 6 (60.0%) 5 (50.0%)
6 - 11.9 (n = 19) 8 (42.1%) 9 (47.4%) 13 (68.4%)
> 11.9 (n = 31) 11 (35.5%) 10 (32.3%) 14 (45.2%)
Total (n = 60) 25 (41.7%) 25 (41.7%) 32 (53.3%)Hong Koh, et al.
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Table 5. Virologic Response and Pre-Treatment Serum ALT Level
ALT (IU/L) HBeAg (-) anti-HBe (+) HBV-DNA (-)
< 100 (n = 18) 1 (5.6%) 1 (5.6%) 2 (11.1%)
100-199 (n = 21) 12 (57.1%) 11 (52.4%) 15 (71.4%)
200-299 (n = 10) 5 (50.0%) 6 (60.0%) 7 (70.0%)
> 300 (n = 11) 7 (63.6%) 7 (63.6%) 8 (72.7%)
Total (n = 60) 25 (41.7%) 25 (41.7%) 32 (53.3%)
Table 6. Virologic Response and Pre-Treatment Serum HBV-DNA Level
DNA (pg/dL) HBeAg (-) anti-HBe (+) HBV-DNA (-)
< 500 (n = 23) 13 (56.5%) 14 (60.9%) 15 (65.2%)
500 (n = 37) 12 (32.4%) 11 (29.7%) 17 (45.9%)
Total (n = 60) 25 (41.7%) 25 (41.7%) 32 (53.3%)
Table 7. Effect of Age, Gender, ALT and HBV-DNA Levels on Virologic Response
HBeAg (-) anti-HBe (+) HBV-DNA (-)
Age 0.221 0.108 0.202
Gender 0.077 0.046 0.273
ALT 0.018 0.028 0.003
HBV-DNA 0.122 0.367 0.465
All values represent p value analyzed by Cox proportional hazard regression method.
Fig. 1. Predictive cumulative rate of seroconversion of
HBeAg analyzed by Kaplan-Meier method in patients
with chronic hepatitis B. Approximately, a 70% serocon-
version rate can be predicted at year 3.
Fig. 2. Predictive cumulative rate of seroconversion of
HBeAg analyzed by Kaplan-Meier method in patients
with chronic hepatitis B. Approximately, a 65% serocon-
version rate can be predicted at year 3.Lamivudine Therapy for Children with Chronic Hepatitis B
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HBV-DNA had no effect on seroconversion rate of
HBeAg, and anti-HBe. Seroconversion rate of
HBeAg, anti-HBe, and HBV-DNA were significantly
higher in patients with elevated pre-treatment
serum ALT (p = 0.018, 0.028, and 0.003) (Table 7).
During therapy, only 6 (10%) patients had
breakthrough phenomenon of serum ALT and
HBV-DNA. Among these patients, 3 had YMDD
mutation, with breakthroughs occurring at 12, 13,
and 22 months after initiation of lamivudine. Of
the 3 (5%) patients, 2 had both YIDD (methionine
isoleucine) and L528M mutations, and 1 had
only YIDD mutation. Relapse occurred in 2 (3.3%)
patients. In 1 patient, seroconversion occurred at
14 months after initiation of therapy, with re-
detection of HBV-DNA at 21 months. In the other
patient, seroconversion occurred at 6 months
therapy with HBV-DNA detection at 16 months.
DISCUSSION
Lamivudine is effective for repression of
necroinflammation, liver fibrosis, seroconversion
of serum HBV-DNA and HBeAg, and normalization
of serum ALT.
6,14,15
Sokal et al.
16 reported mean seroconversion
rates of 48% and 35% for HBV-DNA and HBeAg
in patients 2 to 17 years following 1 year of
lamivudine. Jonas et al.
17 reported 61% and 26%
seroconversion rates of HBV-DNA and HBeAg in
patients 2 to 17 years following treatment with 3
mg/kg for 52 weeks. Ozgenc et al.18 reported that
seroconversion was achieved in 15.6% (7/45) and
5.6% (2/36) at the end of first and second year,
and 0% (none) at the end of third and fourth year
with lamivudine therapy, respectively. In our
study, mean seroconversion rates of HBV-DNA
and HBeAg were 53% and 42% in Korean patients
2 to 17 years, respectively, following treatment with
3 mg/kg for varying duration. Using Kaplan-
Meier method, predicted cumulative seroconversion
rates at 3 years were 68% and 70% for HBV-DNA
and HBeAg, respectively.
Sokal et al.
16 reported a 40% and 24% HBeAg
seroconversion rate HBeAg in patients younger
than 7 years and aged 7 to 12 years, respectively.
Similarly, in this study, the seroconversion rate
was 60% in Korean patients younger than 6 years,
and 42.1% in Korean patients 6 to 12 years.
Liberek et al.
19 studied 59 patients with chronic
hepatitis B aged 6 to 18 years. They reported a
significant influence of pre-treatment serum HBV-
DNA (p = 0.001) on seroconversion rates for HBV-
DNA and HBeAg, however age (p = 0.07), gender
(p = 0.72), and pre-treatment serum ALT (p = 0.14)
had no influence. Alexander et al.
20 studied 60
patients with chronic hepatitis B aged 4 to 80
years. They reported a significant influence of
pre-treatment serum ALT (p = 0.002) and HBV-
DNA (p = 0.004) on seroconversion rates for
HBeAg, however age, gender, and liver cirrhosis
had no influence. In this study, pre-treatment serum
ALT had a significant influence on seroconversion
of HBV-DNA (p = 0.03), HBeAg (p = 0.018) and
anti-HBe (p= 0.028), but not on age, gender, or pre-
treatment HBV-DNA.
In lamivudine therapy group previously treated
with placebo, Sokal et al.
16 reported YMDD
mutation incidence increased from 0% at baseline,
to 19% at 12 months, and to 49% at 24 months.
In lamivudine therapy group previously treated
with lamivudine, YMDD mutation incidence
increased from 24% at baseline, to 59% at 12 months,
and to 64% at 24 months. Ozgenc et al.
18 reported
that breakthrough incidence was detected in six
(13.3%) cases at 12 months and increased to 69.4%
(n = 25) and 82.4% (n = 14) at the end of the
second and third years with lamivudine therapy,
Fig. 3. Predictive cumulative rate of seroconversion of
HBeAg analyzed by Kaplan-Meier method in patients
with chronic hepatitis B. Approximately, a 68% serocon-
version rate can be predicted at year 3.Hong Koh, et al.
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respectively. Hartman et al.
21 reported that YMDD
mutants were detected in 11 of 17 (65%) children
after 1 year of lamivudine treatment. Among
children with YMDD mutant variants, 54%
maintained normal ALT values and 45% had
undetectable HBV DNA by hybridization assay.
In this study, breakthrough phenomenon developed
in only 6 (10%) Korean patients; 3 (5%) had
YMDD mutation at 12, 13, and 22 months following
lamivudine initiation. YIDD mutation (methionin
isoleucine) and L528M mutation were present
in 2 of the 3, and the other patient had only YIDD
mutation. Patients with breakthrough received
adefovir. We suspected the reason of lower
incidence of YMDD mutation might be caused by
somewhat geographical, epidemiological, and
genetic differences, but exactly did not know the
reason. So we had a plan to evaluate the genotype
in the next report and liver biopsies were not
performed. Relapse occurred in 2 (3.3%) Korean
patients. One patient seroconverted at 14 months
with HBV-DNA reoccurrence at 21 months fol-
lowing initiation. The other patient seroconverted
at 6 months and had HBV-DNA reoccurrence at
16 months.
In conclusion, our study showed that pre-treat-
ment ALT was an important factor influencing
virologic response. The seroconversion rate for
HBV-DNA, HBeAg, breakthrough, YMDD muta-
tion, and relapse was 53%, 42%, 10%, 5%, and
3.3%, respectively. Despite high seroconversion
rates in Korean children treated with lamivudine,
new therapeutic agents are needed for improved
viral suppression and reduction of emergence of
resistance.
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